Henoch-Schönlein Purpura: What to expect

Detalhes bibliográficos
Autor(a) principal: Gaia,Maria João
Data de Publicação: 2019
Outros Autores: Capela,Mariana, Borges,Joana Pires, Marques,Eduarda, Ferreira,Graça, Vinhas da Silva,António
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400004
Resumo: Introduction: Henoch-Schönlein Purpura is the most common systemic small vessel vasculitis of childhood. It is most frequently a selflimited entity, although some cases with concomitant nephritis may have serious complications. This study aims to analyze the clinical, epidemiologic and prognostic factors of children with this disease. Methods: Observational and retrospective study of children with diagnosis of Henoch-Schönlein Purpura from January 2011 to June 2017. Results: 61 patients were identified, with a median age of 6 years and a slight predominance of females. Purpura was present in all cases; the second most common symptom was arthralgia (75.4%), followed by gastrointestinal (39.3%), renal (31.1%) and scrotal involvement (6.6%). Corticotherapy was used in 12 patients (19.7%). Almost one fourth of the patients had a recurrence, but only 4 had persistent manifestations for longer than 6 months. Abdominal symptoms were found to have a positive correlation with renal involvement and corticotherapy showed no protective long-term effects. Discussion: Henoch-Schönlein Purpura is mostly a self-limited pathology. We found no association between age or sex and a poorer outcome, but a correlation between abdominal and renal involvement was found. We found a negative correlation between joint involvement and recurring episodes, showing that it may be a good prognostics factor. Corticotherapy demonstrated no protective long-term effect, and was on the contrary correlated with hospitalization, recurrence and persistence of signs and/or symptoms. This correlation can be explained by the fact that patients having indication for and receiving corticotherapy had an inherently more severe spectrum of the disease and so were more prone to poorer outcomes.
id RCAP_f2cd2e7b979637421b107096558e446e
oai_identifier_str oai:scielo:S0872-01692019000400004
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Henoch-Schönlein Purpura: What to expectCorticosteroidsHenoch-SchönleinPurpuraVasculitisIntroduction: Henoch-Schönlein Purpura is the most common systemic small vessel vasculitis of childhood. It is most frequently a selflimited entity, although some cases with concomitant nephritis may have serious complications. This study aims to analyze the clinical, epidemiologic and prognostic factors of children with this disease. Methods: Observational and retrospective study of children with diagnosis of Henoch-Schönlein Purpura from January 2011 to June 2017. Results: 61 patients were identified, with a median age of 6 years and a slight predominance of females. Purpura was present in all cases; the second most common symptom was arthralgia (75.4%), followed by gastrointestinal (39.3%), renal (31.1%) and scrotal involvement (6.6%). Corticotherapy was used in 12 patients (19.7%). Almost one fourth of the patients had a recurrence, but only 4 had persistent manifestations for longer than 6 months. Abdominal symptoms were found to have a positive correlation with renal involvement and corticotherapy showed no protective long-term effects. Discussion: Henoch-Schönlein Purpura is mostly a self-limited pathology. We found no association between age or sex and a poorer outcome, but a correlation between abdominal and renal involvement was found. We found a negative correlation between joint involvement and recurring episodes, showing that it may be a good prognostics factor. Corticotherapy demonstrated no protective long-term effect, and was on the contrary correlated with hospitalization, recurrence and persistence of signs and/or symptoms. This correlation can be explained by the fact that patients having indication for and receiving corticotherapy had an inherently more severe spectrum of the disease and so were more prone to poorer outcomes.Sociedade Portuguesa de Nefrologia2019-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400004Portuguese Journal of Nephrology & Hypertension v.33 n.4 2019reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400004Gaia,Maria JoãoCapela,MarianaBorges,Joana PiresMarques,EduardaFerreira,GraçaVinhas da Silva,Antónioinfo:eu-repo/semantics/openAccess2024-02-06T17:05:04Zoai:scielo:S0872-01692019000400004Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:19:02.967845Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Henoch-Schönlein Purpura: What to expect
title Henoch-Schönlein Purpura: What to expect
spellingShingle Henoch-Schönlein Purpura: What to expect
Gaia,Maria João
Corticosteroids
Henoch-Schönlein
Purpura
Vasculitis
title_short Henoch-Schönlein Purpura: What to expect
title_full Henoch-Schönlein Purpura: What to expect
title_fullStr Henoch-Schönlein Purpura: What to expect
title_full_unstemmed Henoch-Schönlein Purpura: What to expect
title_sort Henoch-Schönlein Purpura: What to expect
author Gaia,Maria João
author_facet Gaia,Maria João
Capela,Mariana
Borges,Joana Pires
Marques,Eduarda
Ferreira,Graça
Vinhas da Silva,António
author_role author
author2 Capela,Mariana
Borges,Joana Pires
Marques,Eduarda
Ferreira,Graça
Vinhas da Silva,António
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Gaia,Maria João
Capela,Mariana
Borges,Joana Pires
Marques,Eduarda
Ferreira,Graça
Vinhas da Silva,António
dc.subject.por.fl_str_mv Corticosteroids
Henoch-Schönlein
Purpura
Vasculitis
topic Corticosteroids
Henoch-Schönlein
Purpura
Vasculitis
description Introduction: Henoch-Schönlein Purpura is the most common systemic small vessel vasculitis of childhood. It is most frequently a selflimited entity, although some cases with concomitant nephritis may have serious complications. This study aims to analyze the clinical, epidemiologic and prognostic factors of children with this disease. Methods: Observational and retrospective study of children with diagnosis of Henoch-Schönlein Purpura from January 2011 to June 2017. Results: 61 patients were identified, with a median age of 6 years and a slight predominance of females. Purpura was present in all cases; the second most common symptom was arthralgia (75.4%), followed by gastrointestinal (39.3%), renal (31.1%) and scrotal involvement (6.6%). Corticotherapy was used in 12 patients (19.7%). Almost one fourth of the patients had a recurrence, but only 4 had persistent manifestations for longer than 6 months. Abdominal symptoms were found to have a positive correlation with renal involvement and corticotherapy showed no protective long-term effects. Discussion: Henoch-Schönlein Purpura is mostly a self-limited pathology. We found no association between age or sex and a poorer outcome, but a correlation between abdominal and renal involvement was found. We found a negative correlation between joint involvement and recurring episodes, showing that it may be a good prognostics factor. Corticotherapy demonstrated no protective long-term effect, and was on the contrary correlated with hospitalization, recurrence and persistence of signs and/or symptoms. This correlation can be explained by the fact that patients having indication for and receiving corticotherapy had an inherently more severe spectrum of the disease and so were more prone to poorer outcomes.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400004
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400004
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400004
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Nefrologia
publisher.none.fl_str_mv Sociedade Portuguesa de Nefrologia
dc.source.none.fl_str_mv Portuguese Journal of Nephrology & Hypertension v.33 n.4 2019
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137280185597952